40MO First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status

40MO First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status

Saved in:
Bibliographic Details
Published in:ESMO open Vol. 9; p. 103540
Main Authors: Van Nieuwenhuysen, E., Chon, H.S., Pepin, J. Thomes, Sundborg, M., Gold, M., Kim, B-G., Blank, S.V., Liu, J., McCollum, M., Mori, M., Moore, K.N., Joseph de Pádua, C., Martinez-Garcia, J., Papadimitriou, C., Grisan, K., Póka, R.L., Donnelly, C., Liu, X., Westin, S.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-06-2024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2024.103540